INMD - InMode's BodyTite Procedure Is Less Attractive Than Investors Assume

InMode (INMD), an Israeli aesthetic medtech company, has developed and commercialized a broad portfolio of proprietary designed Radio Frequency ((RF)) instruments. INMD derives 80% of its revenue in the US and attributes its strength to the following: Technology that kills fat and tightens skin; Product portfolio, branded as the broadest RF-based range of aesthetic treatments; Clinical data with 18 FDA clearances and 44 peer-reviewed publications; Experienced management team.

INMD Q3-19 results looks impressive:

• Projected 2019WW sales of $151M
• Q3 revenue growth of 57% vs year ago
• Gross margin of 87%
• Operating margin of 40%
• $166M